FindTrial
Sign In

The efficacy and safety of Warfarin and Rivaroxaban to prevent re-occlusion for Budd-Chiari syndrome with membranous obstruction after percutanouse balloon angioplasty

To compare the efficacy and safety of Warfarin and Rivaroxaban to prevent re-occlusion for Budd-Chiari syndrome with membranous obstruction after percutanouse balloon angioplasty

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046725
Enrollment
Unknown
Registered
2021-05-27
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Budd-Chiari syndrome

Interventions

Warfarin group:oral take Warfarin
Rivaroxaban group:oral take rivaroxaban

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Membranous obstruction (<3cm) Budd-Chiari syndrome.

Exclusion criteria

Exclusion criteria: 1. Severe heart, liver and kidney dysfunction; 2. Blood coagulation dysfunction, with bleeding tendency; 3. The age is less than 18 years old or more than 75 years old; 4. Combined with liver tumor; 5. Those who are allergic to warfarin or rivaroxaban; 6. No informed consent was obtained.

Design outcomes

Primary

MeasureTime frame
Incidence of re-occlusion;—

Secondary

MeasureTime frame
Bleeding event;Thrombus event;—

Countries

China

Contacts

Public ContactDing Pengxu

The First Affiliated Hospital of Zhengzhou University

jieru375@sina.com+86 13653865950

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026